Back to Search Start Over

Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac-Rhythm Safety of Drug Therapy in the COVID-19 Pandemic. The QT-logs study.

Authors :
Maille, Baptiste
Wilkin, Marie
Million, Matthieu
Rességuier, Noémie
Franceschi, Frédéric
Koutbi-Franceschi, Linda
Hourdain, Jérôme
Martinez, Elisa
Zabern, Maxime
Gardella, Christophe
Tissot-Dupont, Hervé
Singh, Jagmeet P.
Deharo, Jean-Claude
Fiorina, Laurent
Source :
International Journal of Cardiology. May2021, Vol. 331, p333-339. 7p.
Publication Year :
2021

Abstract

QTc interval monitoring, for the prevention of drug-induced arrhythmias is necessary, especially in the context of coronavirus disease 2019 (COVID-19). For the provision of widespread use, surrogates for 12‑lead ECG QTc assessment may be useful. This prospective observational study compared QTc duration assessed by artificial intelligence (AI-QTc) (Cardiologs®, Paris, France) on smartwatch single‑lead electrocardiograms (SW-ECGs) with those measured on 12‑lead ECGs, in patients with early stage COVID-19 treated with a hydroxychloroquine−azithromycin regimen. Consecutive patients with COVID-19 who needed hydroxychloroquine−azithromycin therapy, received a smartwatch (Withings Move ECG®, Withings, France). At baseline, day-6 and day-10, a 12‑lead ECG was recorded, and a SW-ECG was transmitted thereafter. Throughout the drug regimen, a SW-ECG was transmitted every morning at rest. Agreement between manual QTc measurement on a 12‑lead ECG and AI-QTc on the corresponding SW-ECG was assessed by the Bland-Altman method. 85 patients (30 men, mean age 38.3 ± 12.2 years) were included in the study. Fair agreement between manual and AI-QTc values was observed, particularly at day-10, where the delay between the 12‑lead ECG and the SW-ECG was the shortest (−2.6 ± 64.7 min): 407 ± 26 ms on the 12‑lead ECG vs 407 ± 22 ms on SW-ECG, bias −1 ms, limits of agreement −46 ms to +45 ms; the difference between the two measures was <50 ms in 98.2% of patients. In real-world epidemic conditions, AI-QTc duration measured by SW-ECG is in fair agreement with manual measurements on 12‑lead ECGs. Following further validation, AI-assisted SW-ECGs may be suitable for QTc interval monitoring. REGISTRATION: ClinicalTrial.gov NCT04371744. • Artificial intelligence fairly interpreted QTc • Single lead smartwatch ECG is an option for home monitoring ECG • Because of social distancing necessity with COVID-19, home monitoring ECG is crucial. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01675273
Volume :
331
Database :
Academic Search Index
Journal :
International Journal of Cardiology
Publication Type :
Academic Journal
Accession number :
149532798
Full Text :
https://doi.org/10.1016/j.ijcard.2021.01.002